Mr. Jacek Antas reports

HELIX BIOPHARMA CORP. ANNOUNCES UPCOMING POSTER PRESENTATION AT THE 20TH EUROPEAN MOLECULAR IMAGING MEETING IN BILBAO, SPAIN

A poster presentation highlighting the effects of Helix BioPharma Corp.'s tumour defence breaker, L-DOS47, in CEACAM6-expressing head and neck cancer cells and colon adenocarcinoma cells in tumour-bearing mice, will be held at the 20th European Molecular Imaging Meeting on March 11 to March 14 in Bilbao, Spain.

The study demonstrated that L-DOS47 effectively neutralizes the acidic tumour microenvironment in new CEACAM6-expressing solid tumours, a critical factor in tumour progression and immune evasion. In head and neck cancer and colon adenocarcinoma models, treatment with L-DOS47 raised tumour pH levels within 24 hours with a transient but measurable effect lasting up to 48 hours, effectively neutralizing acidity that fuels tumour growth. MRI scans and tissue analysis also revealed signs of tumour necrosis, underscoring L-DOS47's impact on tumour viability. Importantly, the study confirmed that L-DOS47 precisely targets CEACAM6-expressing tumours while being safely cleared from the body. These results add to the growing evidence that L-DOS47 is a powerful tumour defence breaker, shifting the tumour microenvironment to make prevalent, hard-to-treat cancers more vulnerable to treatment.

Poster details

Title:  paradigm change in oncoimmunology: tumour antigen-specific normalization of the extracellular pH in the tumour microenvironment of solid tumours by L-DOS47

Session:  poster session I

Presentation date:  Wednesday, March 12, 2025

Abstract No.:  ONCO-011

Presenters:  Dimitri Stowbur, PhD, postdoctoral reasearch fellow in cancer immunotherapy and modulation of the tumor microenvironment, and Csaba Toemboely, PhD, senior researcher in imaging probe development and cancer immunotherapy, at the University of Tuebingen

About the European Molecular Imaging Meeting annual meeting

The European Molecular Imaging Meeting is a leading international conference dedicated to advancing molecular imaging and its applications in biomedical research. Organized by the European Society for Molecular Imaging, the 20th EMIM brings together over 1,100 scientists, clinicians and industry experts to explore the latest breakthroughs in imaging technologies, biomarkers and translational research. The 2025 meeting will take place in Bilbao, Spain, from March 11 to March 14, providing a platform for cutting-edge presentations, collaborative discussions and emerging innovations that drive the future of molecular imaging.

About Helix BioPharma Corp.

Helix BioPharma is an oncology company shaping a near future where today's hard-to-treat cancers are made vincible by novel therapies that rise to the challenge. The company innovates from strength to tackle cancer's biggest, most urgent challenges with a diverse pipeline of drug candidates with great potential and a head start, honed into first- and best-in-class oncology medicines. Its pipeline is spearheaded by a clinical-stage proprietary technology platform of bioconjugates that score with precision against prevalent CEACAM6-expressing solid tumours. Its lead candidate, tumour defence breaker L-DOS47, is a clinical-stage antibody-enzyme conjugate that neutralizes the microenvironment of common, hard-to-treat solid tumours, taking the brakes off anti-cancer immunity and delivering a game-changing assist to today's front-running anti-cancer therapies. L-DOS47 has completed phase Ib studies in non-small-cell lung cancer (NSCLC), with novel strategically designed bispecific ADCs targeting CEACAM6 in discovery.

Helix is listed on the Toronto Stock Exchange under the symbol HBP, on the OTC Pink under the symbol HBPCD and on the Frankfurt Stock Exchange under the symbol HBP0.

We seek Safe Harbor.